Tear Fluid α-Synuclein Shows Promise as Noninvasive Biomarker for Parkinson’s Disease

A new cross-sectional pilot study published in BMC Neurology suggests that a surprisingly accessible fluid — tears — may offer a noninvasive window into this pathology. Researchers report that total α-synuclein measured in non-stimulated basal tears was significantly higher in patients with Parkinson’s disease than in age- and sex-matched healthy controls, delivering a level of diagnostic separation that could support future screening strategies.

The study, led by Man Luo, Guoyong Qin and Ming Xu, enrolled 34 patients with Parkinson’s disease and 27 healthy controls. Rather than using reflex or stimulated tears, the team collected basal tears — the moisture that naturally coats the eye — by capillary siphon without any ocular stimulation.

Total α-synuclein concentrations were quantified with an electrochemiluminescence immunoassay from Meso Scale Discovery. Between-group comparisons were performed with the Mann-Whitney U test, and diagnostic performance was assessed through receiver operating characteristic (ROC) curve analysis, with Spearman’s rank correlation used to probe any relationship between tear marker levels and clinical severity.

The central result was striking. Tear total α-synuclein levels were significantly higher in the Parkinson’s group than in controls, with a median of 67.26 picograms per milliliter (interquartile range 36.24–99.28) versus 25.78 picograms per milliliter (interquartile range 18.35–47.10). The difference was highly statistically significant, with a P value below 0.001 and a large effect size corresponding to Cohen’s d of 0.99 — indicating that, in this sample, the groups were separated by nearly a full standard deviation.

Diagnostic performance was promising but not definitive. The area under the ROC curve reached 0.781, with a 95 percent confidence interval of 0.662 to 0.900. At a cutoff of 33.55 picograms per milliliter, the test showed a sensitivity of 88.24 percent, correctly identifying most patients, while specificity was 66.67 percent, meaning roughly one in three healthy controls would also test above the threshold. The authors note that the results were robust to the exclusion of two statistical outliers, with the area under the curve remaining at 0.767 in that sensitivity analysis.

One of the more intriguing findings was what the marker did not do. Tear α-synuclein levels showed no significant correlation with clinical severity measures: the correlation with UPDRS-III motor scores was ρ = −0.171 (P = 0.335), with Hoehn-Yahr stage ρ = 0.050 (P = 0.780), and with disease duration ρ = −0.058 (P = 0.747). In other words, the tear marker appears to function as a diagnostic signal — distinguishing patients from controls — rather than as a tracker of how far the disease has progressed in an individual.

The authors conclude that tear total α-synuclein in non-stimulated basal tears showed promising diagnostic performance in what they describe as a predominantly mid-stage cohort. They are careful, however, to frame the work as a pilot: the sample was modest, the design was cross-sectional, and the cohort did not include patients at the earliest stages of disease or those not yet taking medication. Validation in larger, multi-center cohorts that include early-stage and drug-naive patients is explicitly called for before any clinical use could be considered.

The study builds on a growing body of work exploring peripheral fluids as carriers of α-synuclein signatures.

For now, the findings should be read as an encouraging proof of concept rather than a ready-made clinical test. The moderate specificity at the reported cutoff, the mid-stage patient population, and the lack of correlation with disease severity all underscore the need for cautious interpretation. Yet the combination of a large effect size, high sensitivity, and a collection method that is noninvasive makes tear fluid an attractive candidate medium for biomarker development. If larger validations confirm these results — particularly in early and drug-naive patients — a simple tear sample could one day help clinicians identify Parkinson's disease earlier than motor symptoms alone allow.

Subject of Research: Tear fluid total α-synuclein as a diagnostic biomarker for Parkinson's disease

Article Title: Tear fluid total α-synuclein as a diagnostic biomarker for Parkinson’s disease: a cross-sectional pilot study using non-stimulated basal tears

Article References: Luo, M., Qin, G., & Xu, M. (2026). Tear fluid total α-synuclein as a diagnostic biomarker for Parkinson’s disease: a cross-sectional pilot study using non-stimulated basal tears. BMC Neurology. https://doi.org/10.1186/s12883-026-05562-5

Image Credits: AI Generated

DOI: 10.1186/s12883-026-05562-5

Keywords: Parkinson's disease, α-synuclein, tear fluid, biomarker, diagnostics, ROC analysis, pilot study, noninvasive testing, BMC Neurology, electrochemiluminescence immunoassay, Tear, fluid